Cargando…

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer

PURPOSE: The aim of this study was to identify factors associated with progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC) treated with eribulin in a real-world setting, to improve information provision in those considering treatment. METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coe, Faye, Misra, Vivek, McCabe, Yamini, Adderley, Helen, Woodhouse, Laura, Ayub, Zaheen, Wang, Xin, Howell, Sacha, Ekholm, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831340/ https://www.ncbi.nlm.nih.gov/pubmed/34843027 http://dx.doi.org/10.1007/s10549-021-06438-7

Ejemplares similares

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2021)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
por: Garnett, Sally Anne, et al.
Publicado: (2013)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
por: Cortes, Javier, et al.
Publicado: (2015)

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
por: Fukada, Ippei, et al.
Publicado: (2021)

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
por: Masuda, Norikazu, et al.
Publicado: (2021)

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
por: Behrouzi, Roya, et al.
Publicado: (2023)

Eribulin for the treatment of advanced breast cancer: A prospective observational registry study
por: Kenny, Laura, et al.
Publicado: (2022)

Adaptation to average duration
por: Corbett, Jennifer E., et al.
Publicado: (2020)

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
por: Shitara, Kohei, et al.
Publicado: (2023)

A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2‐Negative Breast Cancer
por: Lim, Bora, et al.
Publicado: (2020)

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
por: Pivot, X., et al.
Publicado: (2016)

The REVIVE Study: Long Term Outcomes of a Novel Non-Diffractive Extended Vision IOL versus Monofocal Control IOL
por: Shafer, Brian M, et al.
Publicado: (2022)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Facts on the Question of the Average Duration of Pregnancy
por: Mackay, Geo.
Publicado: (1858)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women
por: Evans, D. Gareth, et al.
Publicado: (2021)

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants
por: Evans, D. Gareth R., et al.
Publicado: (2019)

Comparison of the effect of the pelvic floor muscle biofeedback prior or postradical prostatectomy on urinary incontinence: A randomized controlled trial
por: Allameh, Farzad, et al.
Publicado: (2022)

IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients
por: Palmieri, Carlo, et al.
Publicado: (2017)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
por: Jafri, Mariam, et al.
Publicado: (2022)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

2224: Characterizing vigilant thoughts and behaviors that disrupt sleep in veterans and utilization of cognitive techniques
por: Katherine Howell, Mary, et al.
Publicado: (2018)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
por: Silverman, Stuart L.
Publicado: (2010)

Feasibility and benefits of group-based exercise in residential aged care adults: a pilot study for the GrACE programme
por: Fien, Samantha, et al.
Publicado: (2016)

Two-Year Outcomes of Cochlear Implant Use for Children With Unilateral Hearing Loss: Benefits and Comparison to Children With Normal Hearing
por: Park, Lisa R., et al.
Publicado: (2023)

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
por: Yardley, Denise A., et al.
Publicado: (2012)

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qla55duvmhcabs3bdibi9a7cpm